AR040709A1 - Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion - Google Patents

Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion

Info

Publication number
AR040709A1
AR040709A1 AR20030102702A ARP030102702A AR040709A1 AR 040709 A1 AR040709 A1 AR 040709A1 AR 20030102702 A AR20030102702 A AR 20030102702A AR P030102702 A ARP030102702 A AR P030102702A AR 040709 A1 AR040709 A1 AR 040709A1
Authority
AR
Argentina
Prior art keywords
formulation
lamotrigine
release
same
lamotrigin
Prior art date
Application number
AR20030102702A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217492A external-priority patent/GB0217492D0/en
Priority claimed from GB0217493A external-priority patent/GB0217493D0/en
Priority claimed from GB0313801A external-priority patent/GB0313801D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR040709A1 publication Critical patent/AR040709A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

Formulación de lamotrigina o de uno de sus derivados farmacéuticamente aceptables la cual es una formulación de liberación prolongada. Sustancialmente toda la lamotrigina o uno de sus derivados farmacéuticamente aceptables se libera de la formulación 2 a 20 horas después de la administración al paciente. La formulación de liberación prolongada tiene un perfil de disolución in vitro en el que 40 a 65% de la lamotrigina se disuelve en 3 a 8 horas. Preferentemente la liberación de la lamotrigina se produce en al menos dos fases presentes en la formulación, en las que la velocidad de liberación de la primera fase es diferente a la velocidad de liberación de la segunda fase. Uso de lamotrigina para preparar la formulación de liberación prolongada para tratar trastornos del CNS. De la misma manera se reduce la frecuencia de al menos un efecto secundario asociado a la administración de lamotrigina y se logra una concentración en suero que, tras administrar a un paciente la formulación de lamotrigina de liberación prolongada se produce una Cmax que es alrededor de 30% menor que la de un comprimido de liberación instantánea que contenga la misma cantidad de almotrigina.
AR20030102702A 2002-07-29 2003-07-28 Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion AR040709A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0217492A GB0217492D0 (en) 2002-07-29 2002-07-29 Novel method of treatment
GB0217493A GB0217493D0 (en) 2002-07-29 2002-07-29 Novel methods of treatment
GB0313801A GB0313801D0 (en) 2003-06-13 2003-06-13 Novel methods of treatment

Publications (1)

Publication Number Publication Date
AR040709A1 true AR040709A1 (es) 2005-04-13

Family

ID=31499035

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102702A AR040709A1 (es) 2002-07-29 2003-07-28 Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion

Country Status (29)

Country Link
US (1) US20050032799A1 (es)
EP (1) EP1524981B1 (es)
JP (2) JP4744142B2 (es)
KR (1) KR100882707B1 (es)
CN (1) CN100363007C (es)
AR (1) AR040709A1 (es)
AT (1) ATE424827T1 (es)
AU (1) AU2003260336C1 (es)
BR (1) BRPI0313148B8 (es)
CA (1) CA2493301A1 (es)
CO (1) CO5680405A2 (es)
CY (1) CY1109119T1 (es)
DE (1) DE60326590D1 (es)
DK (1) DK1524981T3 (es)
ES (1) ES2323268T3 (es)
HK (1) HK1077003A1 (es)
IL (1) IL166424A (es)
IS (1) IS2681B (es)
MA (1) MA27509A1 (es)
MX (1) MXPA05001243A (es)
MY (1) MY141049A (es)
NO (1) NO334221B1 (es)
NZ (1) NZ537885A (es)
PL (1) PL213565B1 (es)
PT (1) PT1524981E (es)
RU (1) RU2325163C2 (es)
SI (1) SI1524981T1 (es)
TW (1) TWI342213B (es)
WO (1) WO2004012741A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
MXPA05001243A (es) * 2002-07-29 2005-06-08 Glaxo Group Ltd Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion.
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
MX2007012374A (es) * 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
WO2008109343A1 (en) * 2007-03-01 2008-09-12 Memory Pharmaceuticals Corporation Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2010009433A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
MX2012006320A (es) 2009-12-02 2013-01-18 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
WO2011086568A1 (en) * 2010-01-13 2011-07-21 Accutest Research Laboratories (I) Pvt. Ltd Controlled release composition for lamotrigine
KR20140016260A (ko) * 2011-02-03 2014-02-07 루핀 리미티드 베포타스틴의 경구용 방출 조절 약제 조성물
WO2014159275A1 (en) * 2013-03-14 2014-10-02 PharmTak, Inc. Controlled-release pharmaceutical compositions comprising lamotrigine and methods of producing same
CN103920134A (zh) * 2014-05-08 2014-07-16 崔韡 一种治疗儿童眩晕的缓释片及其制备方法
RU2624229C2 (ru) * 2015-12-21 2017-07-03 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с замедленным высвобождением и способ их получения
RU2613192C1 (ru) * 2016-02-18 2017-03-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с пролонгированным высвобождением
JP2020506245A (ja) * 2017-02-03 2020-02-27 ジュビラント ジェネリックス リミテッドＪｕｂｉｌａｎｔ Ｇｅｎｅｒｉｃｓ Ｌｉｍｉｔｅｄ ラモトリギン懸濁液剤形
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
JP2021500083A (ja) * 2017-10-27 2021-01-07 チャン グァン メモリアル ホスピタル，リンコウＣｈａｎｇ Ｇｕｎｇ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ，Ｌｉｎｋｏｕ 抗てんかん薬ラモトリギンにより誘発される薬剤による皮膚副作用の危険性を評価する方法、その検出試薬、およびその使用
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
CN114948868B (zh) * 2021-04-16 2023-04-14 上海奥科达医药科技股份有限公司 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
JPH0667828B2 (ja) * 1985-10-09 1994-08-31 日研化学株式会社 バルプロ酸ナトリウムの持続性顆粒製剤
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
DE69207863T2 (de) * 1991-11-13 1996-06-05 Glaxo Canada Vorrichtung zur kontrollierten Wirkstoffreigabe
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
AU4078897A (en) * 1996-08-23 1998-03-06 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
GB9625795D0 (en) * 1996-12-12 1997-01-29 Smithkline Beecham Plc Novel treatment
US6046716A (en) * 1996-12-19 2000-04-04 Colorado Microdisplay, Inc. Display system having electrode modulation to alter a state of an electro-optic layer
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
NZ511465A (en) * 1998-11-02 2003-10-31 Alza Corp Controlled delivery of active agents
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0024517D0 (en) * 2000-10-06 2000-11-22 Glaxo Group Ltd Use of medicaments
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
MXPA05001243A (es) * 2002-07-29 2005-06-08 Glaxo Group Ltd Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion.

Also Published As

Publication number Publication date
ATE424827T1 (de) 2009-03-15
US20050032799A1 (en) 2005-02-10
BRPI0313148B8 (pt) 2021-05-25
EP1524981B1 (en) 2009-03-11
NZ537885A (en) 2007-11-30
IS2681B (is) 2010-09-15
RU2325163C2 (ru) 2008-05-27
AU2003260336C1 (en) 2008-05-29
KR20050026054A (ko) 2005-03-14
IL166424A (en) 2010-12-30
JP2005538113A (ja) 2005-12-15
RU2005105353A (ru) 2005-10-27
AU2003260336A1 (en) 2004-02-23
MA27509A1 (fr) 2005-09-01
NO20050948L (no) 2005-02-22
MY141049A (en) 2010-02-25
PL213565B1 (pl) 2013-03-29
CO5680405A2 (es) 2006-09-29
ES2323268T3 (es) 2009-07-10
NO334221B1 (no) 2014-01-13
SI1524981T1 (sl) 2009-08-31
JP4744142B2 (ja) 2011-08-10
WO2004012741A1 (en) 2004-02-12
BRPI0313148B1 (pt) 2019-08-20
MXPA05001243A (es) 2005-06-08
CN1681509A (zh) 2005-10-12
KR100882707B1 (ko) 2009-02-06
DE60326590D1 (de) 2009-04-23
EP1524981A1 (en) 2005-04-27
CN100363007C (zh) 2008-01-23
PT1524981E (pt) 2009-06-17
TW200418484A (en) 2004-10-01
CA2493301A1 (en) 2004-02-12
DK1524981T3 (da) 2009-06-22
TWI342213B (en) 2011-05-21
PL374982A1 (en) 2005-11-14
IS7707A (is) 2005-02-23
CY1109119T1 (el) 2014-07-02
HK1077003A1 (en) 2006-02-03
JP2011057683A (ja) 2011-03-24
IL166424A0 (en) 2006-01-15
BR0313148A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
PT1239849E (pt) Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao
UY27913A1 (es) Forma de dosificacion una vez al dia de pramipexol
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
TW200603787A (en) Topical preparations containing ambroxol
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
HUP0202671A2 (hu) Ketotifen optikailag aktív izomerei és aktív metabolitjai
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
NO20080244L (no) Doseringsstyring for prasugrel
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
MXPA06007510A (es) Composiciones de farmaco y formas de dosis novedosas de topiramato.
PT1150704E (pt) Melagatran para o tratamento da inflamacao
AR047726A1 (es) Metodos y reactivos para el tratamiento de trastornos inflamatorios
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
MA28036A1 (fr) Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil

Legal Events

Date Code Title Description
FC Refusal